Ocular Delivery of the β-Adrenergic Antagonist Alprenolol by Sequential Bioactivation of Its Methoxime Analogue

Laszlo Prokai, Whei Mei Wu, Gabor Somogyi, Nicholas Bodor

Research output: Contribution to journalComment/debate

22 Scopus citations

Abstract

Ocular delivery of alprenolol, a β-adrenergic antagonist, by site-specific bioactivation of its methoxime analogue results in significant and prolonged decrease of the intraocular pressure in rabbits after topical administration. Alprenolone methoxime is stable in isotonic phosphate vehicle but undergoes enzymatic hydrolysis to the corresponding ketone in the eye. The ketone is then converted to alprenolol by a carbonyl reductase present in the iris-ciliary body. The benefit of this chemical delivery system approach includes the facile release of a potential antiglaucoma agent only at the site of the action; thus, unwanted systemic effects of the drug can be avoided.

Original languageEnglish
Pages (from-to)2018-2020
Number of pages3
JournalJournal of Medicinal Chemistry
Volume38
Issue number11
DOIs
StatePublished - 1 May 1995

Fingerprint Dive into the research topics of 'Ocular Delivery of the β-Adrenergic Antagonist Alprenolol by Sequential Bioactivation of Its Methoxime Analogue'. Together they form a unique fingerprint.

  • Cite this